Biotransformation reactions of five-membered aromatic heterocyclic rings

Chemical Research in Toxicology

Volumn 15, Issue 3, 2002, Pages 269-299

  Dalvie, Deepak K ^a   Kalgutkar, Amit S ^a   Khojasteh Bakht, S Cyrus ^b   Obach, R Scott ^a   O'Donnell, John P ^a  

^a PFIZER INC   (United States)

^b GENENTECH INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1,2,3 TRIAZOLE DERIVATIVE; 1,2,4 TRIAZOLE DERIVATIVE; 2 (4 CHLOROPHENYL) 5 (2 FURYL) 4 OXAZOLEACETIC ACID ETHYL ESTER; 3 [6 [7 CYANO 5 (3 FURYL) 2 NAPHTHOXYMETHYL] 2 PYRIDYL] 3 HYDROXY 6,8 DIOXABICYCLO[3.2.1]OCTANE; ANTIHYPERTENSIVE AGENT; ANTILIPEMIC AGENT; ANTIRETROVIRUS AGENT; AROMATIC COMPOUND; BENZOFURAN DERIVATIVE; BENZOTHIOPHENE DERIVATIVE; FURAN DERIVATIVE; HETEROCYCLIC COMPOUND; IMIDAZOLE DERIVATIVE; INDOLE DERIVATIVE; ISOTHIAZOLE DERIVATIVE; ISOXAZOLE DERIVATIVE; L 754394; LIPOXYGENASE INHIBITOR; MOPIDRALAZINE; OXADIAZOLE DERIVATIVE; OXAZOLE DERIVATIVE; PYRAZOLE DERIVATIVE; PYRROLE DERIVATIVE; TENIDAP; TETRAZOLE DERIVATIVE; THIADIAZOLE DERIVATIVE; THIAZOLE DERIVATIVE; THIOPHENE DERIVATIVE; TRIAZOLE DERIVATIVE; UNCLASSIFIED DRUG; UNINDEXED DRUG;

AEROBIC METABOLISM; BIOTRANSFORMATION; CATALYSIS; CHEMICAL STRUCTURE; ENZYME ACTIVITY; HUMAN; LIVER MICROSOME; METABOLITE; MOUSE; NONHUMAN; RAT; REVIEW; STRUCTURE METABOLISM RELATION; XENOBIOTIC METABOLISM;

ANIMALS; CYTOCHROME P-450 ENZYME SYSTEM; FURANS; HETEROCYCLIC COMPOUNDS WITH 4 OR MORE RINGS; HUMANS; IMIDAZOLES; INDOLES; ISOXAZOLES; MODELS, CHEMICAL; MOLECULAR STRUCTURE; OXADIAZOLES; OXAZOLES; PYRAZOLES; PYRROLES; TETRAZOLES; THIADIAZOLES; THIAZOLES; THIOPHENES; TRIAZOLES; XENOBIOTICS;

EID: 0036127307     PISSN: 0893228X     EISSN: None     Source Type: Journal    
DOI: 10.1021/tx015574b     Document Type: Review

References (278)

1. Bioisosterism: A rational approach in drug design
2. Bioisosterism in drug design
3. Metabolic activation and drug toxicity
4. Toxicity of heterocycles
5. Metabolism of heterocycles
6. Pyrroles
7. Five membered ring compounds with one heteroatom
8. Molecular vibrational constants and chemical bonding in five-membered heterocyclic compounds
9. Metabolic activation of model pyrroles by cytochrome P450
10. Carbon oxidations catalyzed by cytochromes P-450
11. Untersuchungen zur biotransformation des antikonvulsivusms 4-p-chlorophenylpyrrol-3-morpholino-2-carbonsauremethylester (AWD 140-076)
12. Metabolic fate of premazepam, a new antianxiety drug, in the rat and the dog
13. Biological inactivation of pyrrolnitrin. Identification and synthesis of pyrrolnitrin metabolites
14. Liver and lung microsomal metabolism of the tobacco alkaloid β-nicotyrine
15. Studies on the pyrrolinone metabolites derived from tobacco alkaloid 1-methyl-2-(3-pyridinyl)pyrrole (β-Nicotyrine)
16. Studies on the in vivo biotransformation of the tobacco alkaloid β-nicotyrine
17. Disposition and metabolism of prinomide in laboratory animals
18. Metabolic pathways of the anti-hypertensive agent, N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride. I. Studies in the rat
19. Metabolic pathways of the anti-hypertensive agent, N-(2,5-dimethyl-1H-pyrrol-1-yl)-6-(4-morpholinyl)-3-pyridazinamine hydrochloride. II. Studies in the dog
20. 13C-labelled drug
21. Pharmacokinetics and metabolism of α-[(dimethylamino)methyl]-2-(3-ethyl-5-methyl-4-isoxazolyl)-1H- indole-3-methanol, a hypoglycemic agent in man
22. Biotransformation of fluvastatin sodium in humans
23. Pharmacokinetics and metabolism of the 5-hydroxytryptamine antagonist tropisetron after single oral doses in humans
24. Multiple forms of cytochrome P 450 are involved in the metabolism of ondansetron in humans
25. 1-adrenoreceptor antagonist indoramin
26. Absortion, distribution, metabolism, and excretion of atervirdine in the rat
27. 14C]indole in the rat
28. Oxidation of indole by cytochrome P 450 enzymes
29. Common and uncommon cytochrome P 450 reactions related to metabolism and chemical toxicity
30. Biotransformation of proterguride in the perfused rat liver
31. The application of hepatocyte culture to the identification of pathways of drug metabolism: Studies with pindolol and fluperlapine
32. Metabolites of pindolol in different animal species
33. Metabolism and disposition of the antifolate LY231514 in mice and dogs
34. Indoleamine 2,3-dioxygenase - A new antioxidant enzyme
35. Photo-oxidation of 5,6-dihydroxyindoles
36. 3-Methylindole-induced acute lung injury resulting from ruminal fermentation of tryptophan
37. Metabolism of 3-methylindole by vaccinia-expressed P450 enzymes: Correlation of 3-methyleneindolenine formation and protein binding
38. Identification of goat and mouse urinary metabolites of the puemotoxin, 3-methylindole
39. Isolation and identification of 3-hydroxy-3-methyloxindole, the major murine metabolite of 3-methylindole
40. Identification of phase I metabolites of 3-methylindole produced by pig liver microsomes
41. Evidence supporting the formation of 2,3-epoxy-3-methylindoline: A reactive intermediate of the puemotoxin 3-methylindole
42. Thioether adducts of a new imine reactive intermediate of the puemotoxin 3-methylindole
43. Identification of a cysteinyl adduct of oxidized 3-methylindole from goat lung and human liver microsomal proteins
44. Isolation of a mercapturate adduct produced by susequent glutathione conjugation to bioactivated 3-methylindole
45. Detection and characterization of DNA adducts of 3-methylindole
46. Mechanistic studies on the cytochrome P450 catalyzed dehydrogenation of 3-methylindole
47. Cloning and expression of CYP2F3, a cytochrome P450 that bioactivates the selective puemotoxins 3-methylindole and naphthalene
48. Specific dehydrogenation of 3-methylindole and epoxidation of naphthalene by recombinant human CYP2F1 expressed in lymphoblastoid cells
49. Selective dehydrogenation/oxygenation of 3-methylindole by cytochrome P450 enzymes
50. Identification of the metabolites of the HIV-1 reverse transcriptase inhibitor delavirdine in monkeys
51. Structural determination of glucuronide conjugates and a carbamoyl glucuronide conjugate of carvedilol: Use of acetylation reactions as an aid to determine positions of glucuronidation
52. The metabolism of pyrroles and indoles. Ring nitrogen oxidation
53. Metabolism and excretion of zafirlukast in dogs, rats and mice
54. Biliary proliferation and adaptation in furan-induced rat liver injury and carcinogenesis
55. A reactive metabolite of furan, cis-2-butene-1,4-dial, is mutagenic in the Ames assay
56. Kinetic analysis of furan biotransformation by F-344 rats in vivo and in vitro
57. 14C]furan in the male F344 rat
58. Identification of cis-2-butene-1,4-dial as a microsomal metabolite of furan
59. Reactive metabolites from the bioactivation of toxic methylfurans
60. Metabolic activation of 2-methylfuran by rat microsomal systems
61. Studies on the interaction of furan with hepatic cytochrome P450
62. Characterization of amino acid and glutathione adducts of cis-2-butene-1,4-dial, a reactive metabolite of furan
63. Renal and hepatic necrosis after metabolic activation of 2-substituted furans and thiophenes, including furosemide and cephalosporine
64. Hepatic necrosis caused by furosemide
65. Furosemide induced hepatotoxicity
66. Role of covalent binding in the toxic mechanism of the lung-edemagenic agent, 4-ipomeanol
67. Role of metabolic activation in the pathogenesis of chemically induced pulmonary disease: Mechanism of action of furan lung-toxic 4-ipomeanol
68. Metabolic activation of furosemide to a chemically reactive, hepatotoxic metabolite
69. Hepatotoxicity produced by the lung-toxic furanoterpenoid, 4-ipomeanol, after mixed function oxidase induction: Reversal of target organ for toxicity and covalent binding in rats pretreated with 3-methylchlolanthrene
70. In vitro studies on the metabolic activation of the pulmonary toxin, 4-ipomeanol, by rat lung and liver microsomes
71. Microsomal metabolism of the 5-lipoxygenase inhibitor L-739,010: Evidence for furan bioactivation
72. In vitro studies on the metabolic activation of the furanopyridine L-754,394, a highly potent and selective mechanism-based inhibitor of cytochrome P450 3A4
73. Metabolic pathway by cleavage of furan
74. The metabolism of 1-phenyl-2-(N-methyl-N-furfurylamino)propane (furfenorex) in the rat in vivo and in vitro
75. 14C-methoxsalen by dog
76. Disposition of 8-methoxypsoralen in the rat: Methodology for measurement, dose-dependent pharmcokinetics, tissue distribution and identification of metabolites
77. The metabolism of the abortifacient terpene R-(+)-pulegone, to a proximate toxin, menthofuran
78. Metabolism of a monoterpene ketone, R-(+)-pulegone a hepatotoxin in rat
79. Metabolic activation of R-(+)-pulegone to a reactive enonal that covalently binds the mouse liver proteins
80. Metabolic fate of menthofuran in rats: Novel oxidative pathways
81. Biotransformations of R-(+)-pulegone and menthofuran in vitro. Chemical basis for toxicity
82. Reactive intermediates in the oxidation of menthofuran by cytochrome P450
83. Metabolism of R-(+)-pulegone and R-(+)-menthofuran by human liver cytochrome P450s: Evidence for formation of a furan epoxide
84. Mechanism of metabolic cleavage of a furan ring
85. Microsomal metabolism of furosemide: Evidence for the nature of the reactive intermediate involved in covalent binding
86. The metabolic activation of nitroheterocyclic therapeutic agents
87. Metabolism in vivo of furazolidone: Evidence for formation of open ehain carboxylic acid and α-ketoglutaric acid from the nitrofuran in rats
88. Isolation and identification of the metabolite of N-(5-nitro-2-furfurylidene)-3-amino-2-oxazolidone (furazolidone)
89. Quantitative studies of the metabolism of furazolidone by rat liver microsomes
90. Metabolism of the nitrofurans. III. Xanthine oxidase in vitro
91. Reduction of niridazole by rat liver xanthine oxidase
92. Nitroreduction of 5-nitrofuran derivatives by rat liver xanthine oxidase and reduced nicotinamide adenine dinucleotide phosphatecytochrome c reductase
93. Reduction of nitrofuran derivatives by xanthine oxidase and microsomes. Isolation and identification of reduction products
94. Nitroreductase activity of mammalian liver aldehyde oxidase
95. Evidence for the involvement of nitrenium ion in the covalent binding of nitrofurazone to DNA
96. Disposition and metabolism of some nitrofurylthiazoles possessing antiparasitic activity
97. Main excretion metabolites of 7-methoxy-2-nitronaphtho[2,1-b]furan (R-7000) in rats
98. The metabolism of thiophene in the rabbit and the rat
99. Hydroxylation of the thiophene ring by hepatic monooxygenases: Evidence for 5-hydroxylation of 2-aroylthiophenes as a general metabolic pathway using a simple UV-visible assay
100. Metabolic hydroxylation of the thiophene ring: Isolation of 5-hydroxy-tienilic acid as the major urinary metabolite of tienilic acid in man and rat
101. Hydroxylation of the thiophene ring: In vitro the 5-hydroxylation of tienilic acid is catalyzed by cytochrome P 450 in rat and human microsomes
102. Further structural analysis of urinary metabolites of suprofen in rats
103. Species differences in the metabolism of suprofen in laboratory animals and man
104. Disposition of a new nonsteroidal antiinflammatory agent, S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid in rats, dogs, and monkeys
105. Metabolism of tenoxicam in rats
106. Absorption, excretion and metabolism of tiquizium bromide in dogs, and relationship between pharmacological effect and plasma levels of unchanged drug
107. The in vitro and in vivo metabolism of morantel in cattle and toxicology species
108. Pharmacokinetics and metabolic characteristics of ticlopidine in relation to its inhibitory properties on platelet function
109. Oxidation of tienilic acid by human yeast-expressed cytochromes P-450 2C8, 2C9, 2C18, and 2C19. Evidence that this drug is a mechanism-based inhibitor specific for cytochrome P-450 2C9
110. Hydroxylation and formation of electrophilic metabolites of tienilic acid and its isomer by human liver microsomes
111. Human liver cytochromes P450 expressed in yeast as tools for reactive metabolite formation studies
112. Identification of human cytochrome P450 isoforms involved in the metabolism of S-2-[4-(3-methyl-2-thienyl)phenyl]propionic acid
113. Disposition and metabolism of tenidap in the rat
114. Evidence for thiophene-S-oxide as a primary reactive metabolite of thiophene in vivo: Formation of a dihydrothiophene sulfoxide mercapturic acid
115. Thiophene-S-oxides as new reactive metabolites: Formation by cytochrome P450 dependent oxidation and reaction with nucleophiles
116. Chemical and biological oxidation of thiophene: Preparation and complete characterization of thiophene-S-oxide as an intermediate in thiophene metabolism in vivo and in vitro
117. Thiophene-S-oxides as reactive metabolites: Formation upon microsomal oxidation of a 3-aroylthiophene and fate in the presence of nucleophiles in vitro and in vivo
118. Thiophene derivatives as new mechanism based inhibitors of cytochromes P450: Inactivation of yeast expressed human liver cytochrome P450 2C9 by tienilic acid
119. Tienilic acid induced autoimmune hepatitis: Anti-liver and -kidney microsomal type 2 autoantibodies recognize a three-site conformational epitope on cytochrome P4502C9
120. Molecular structure and hepatotoxicity: Compared data about two closely related thiophene compounds
121. Electrospray ionization mass spectrometric analysis of intact cytochrome P450: Identification of tienilic acid adducts to P450 2C9
122. Use of isotopes and LC-MS-ESI-TOF for mechanistic studies of tienilic acid and tienilic acid isomer mechanistic activation
123. Opposite behaviors of reactive metabolites of tienilic acid and its isomer toward liver proteins: Use of specific anti-tienilic acid-protein adduct antibodies and the possible relationship with different hepatotoxic effects of the two compounds
124. The microbial metabolism of thiophen-2-carboxylate
125. Oxidative fate of an aryl thiophene: In vivo and in vitro investigation of a possible non-P450 mediated ring opening mechanism
126. Identification of the human liver cytochrome P450 enzymes involved in the metabolism of zileuton (ABT-077) and its N-dehydroxylated metabolite, Abbot-66193
127. Metabolism of ticlopidine by activated neutrophils: Implications for ticlopidine-induced agranulocytosis
128. Five membered ring compounds with two or more heteroatoms
129. Protonation of tetrazole
130. Quaterniztion of heteroaromatic compounds. Quantitative aspects
131. On the relationships between basicity and acidity in azoles
132. Basicity of azoles. IV. Empirical relationships between basicity and ionization potential for aromatic five membered rings containing nitrogen and oxygen
133. Imidazole-versatile today, prominent tomorrow
134. Structure-activity relationships in the effects of 1-alkylimidazoles on microsomal oxidation in vitro and in vivo
135. Synthesis and biological evaluation of imidazole based compounds as cytochrome P-450 inhibitors
136. Structural basis of selective cytochrome P450 inhibition
137. Substrate interaction with cytochrome P450
138. Inhibition of cytochrome P-450 enzymes
139. Steric factors in the inhibitory interaction of imidazoles with microsomal enzymes
140. Comparison of imidazole- and 2-methylimidazole-containing farnesyl protein transferase inhibitors: Interaction with and metabolism by rat hepatic cytochrome P450s
141. The metabolism of imiloxan hydrochloride in healthy male volunteers
142. Investigation and identification of imidazole metabolites in the rat, using thin-layer chromatography, infrared spectroscopy, and mass spectrometry
143. Mammalian metabolism of L-histidine. II. Enzymatic formation, stabilization, purification, and properties of 4(5)-imidazolone-5(4)-propionic acid, the product of urocanase activity
144. Characterization of the reaction intermediates in a model oxidative phosphorylation reaction
145. The metabolism of nafimidone hydrochloride in the dog, primates, and man
146. Disposition of nafimidone in rats
147. 3H]-econazole in man
148. The metabolism and excretion of prochloraz, an imidazole-based fungicide, in the rat
149. Metabolism of an imidazole fungicide (prochloraz) in the rat after oral administration
150. Mouse hepatic metabolites of ketoconazole: Isolation and structure elucidation
151. Mono-oxygenase catalyzed N-C cleavage
152. Disposition of ethimizol, a xanthine-related nootropic drug, in perfused rat liver and isolated hepatocytes
153. Croconazole metabolism in rats
154. Metabolism of the antimycotic agent, croconazole, in rabbits
155. Synthesis and identification of the quaternary ammonium-linked glucuronide of 1-phenylimidazole in human liver microsomes and investigation of the human UDP-glucuronosyltransferases involved
156. N-Glucuronidation reactions. II. Relative N-glucuronidation reactivity of methylbiphenyl tetrazole, methylbiphenyl triazole, and methylbiphenyl imidazole in rat, monkey, and human hepatic microsomes
157. N-Glucuronidation reactions. III. Regioselectivity of N-glucuronidation of methylbiphenyl tetrazole, methylbiphenyl triazole, and methylbiphenyl imidazole using human and rat recombinant UDP-glucuronosyltransferases stably expressed in V79 cells
158. Adverse immunologic effects of antithyroid drugs
159. Adverse effects of thyroid hormone preparations and antithyroid drugs
160. Drug-induced hepatic injury during methimazole therapy
161. Hepatotoxicity from antithyroid drugs
162. Metabolism-dependent hepatotoxicity of methimazole in mice depleted of glutathione
163. Evidence for the involvement of N-methylthiourea, a ring cleavage metabolite, in the hepatotoxicity of methimazole in glutathione-depleted mice: Structure-toxicity and metabolic studies
164. 14C]-methimazole in the rat
165. Loss of rat liver microsomal cytochrome P-450 during methimazole metabolism. Role of flavin-containing monooxygenase
166. Toxicology of thiono-sulfur compounds
167. S-Oxygenation of N-substituted thioureas catalyzed by the pig liver microsomal FAD-containing monooxygenase
168. Structural and catalytic properties of the mammalian flavin-containing monooxygenase
169. Retention mechanism of imidazoles in connective tissue. I. Binding to elastin
170. Retention mechanism of imidazoles in connective tissue. III. Aldehyde adduct formation of a 4(5H) (or 5(4H))-imidazolone product in vitro
171. Retention mechanism of imidazoles in connective tissue. IV. Identification of a nucleophilic imidazolone metabolite in rats
172. Studies on the disposition of fadrazole hydrochloride (CGS 16949A). II. Absorption, distribution, metabolism and excretion after repeated oral administration to rats
173. Irreversible binding to proteins after single and repeated daily oral administration of 4-(2,2-diphenylethyl)imidazole (SC-46264) to the cynomolgus monkey
174. Metabolic and tissue residue studies on parbendazole in sheep
175. The metabolism of benomyl fungicide in mammals
176. Toxicol
177. Identification of 5-hydroxybenzimidazole as a major urinary metabolite of benzimidazole in the rat
178. Characterization of 2-amino-1-benzylimidazole and its metabolites using tandem mass spectrometry
179. Stereoselective metabolism by human liver CYP enzymes of a substituted benzimidazole
180. Metabolism of aminophenols, o-formamidophenol, benzoxazole, 2-methyl- and 2-phenylbenzoxazoles, and benzoxazolone in the rabbit
181. Ditazol metabolism in rat, rabbit, and man
182. On the metabolism of ditazole in man
183. Dose dependent pharmacokinetics of zoxazolamine in the rat
184. The metabolism of isomoxole in the rat and guinea pig
185. Realtive hepatotoxicity of 2-(substituted phenyl)thiazoles and substituted thiobenzamides in mice: Evidence for the involvement of thiobenzamides as ring cleavage metabolites in the hepatotoxicity of 2-phenylthiazoles
186. Formation of toxic metabolites from thiabendazole and other thiazoles in mice: Identification of thioamides as ring cleavage products
187. DL-buthionine sulfoximine
188. Nephrotoxicity of thiazoles strucutrally related to thiabendazole in mice depleted of glutathione by treatment with buthionine sulfoxoimine
189. Possible role of thioformamide as a proximate toxicant in the nephrotoxicity of thiabendazole and related thiazoles in glutathione-depleted mice: Structure-toxicity and metabolic studies
190. Evidence for cytochrome P4501A2-mediated protein covalent binding of thiabendazole and for its passive intestinal transport: Use of human and rabbit derived cells
191. Metabolism of 4-[1-(2-fluoro-4-biphenyl)-ethyl]-2-methylaminothiazole (SM-8849), in rats
192. The metabolism of acetamidothiazoles in the rat: 2-acetamido-, 2-acatamido-4-methyl- and 2-acetamido-4-phenylthiazole
193. Species differences in pharmacokinetics of a hepatoprotective agent, YH-439, and its metabolites M4, M5, and M7, after intravenous and oral administration to rats, rabbits and dogs
194. Metabolism of sudoxicam by the rat, dog and monkey
195. Meloxicam: Metabolic profile and biotransformation products in the rat
196. Metabolism of benzothiazole. I. Identification of ring cleavage products
197. Metabolism of chlormethiazol in the rat
198. Metabolism of chlormethiazol in the perfused liver of the rat
199. 4,5-Dimethylthiazole-N-oxide-S-oxide: A metabolite of chlormethiazole in man
200. Unexpected metabolites produced from chlormethiazole
201. Characterization of the in vitro oxidative metabolites of the COX-2 selective inhibitor L-766,112
202. The biotransformation of a sulphonamide to a mercaptan and to a mercapturic acid and glucuronide conjugates
203. The nonenzymatic displacement of the sulfamoyl group from different classes of aromatic compounds by glutathione and cysteine
204. Metabolism of 2-thiobenzothiazoles in the rat
205. Comparison of the interaction of pyrazole and its metabolite 4-hydroxypyrazole with rat liver microsomes
206. Oxidation of pyrazole by reconstituted systems containing cytochrome P450 2E1
207. Oxidation of pyrazole to 4-hydroxypyrazole in intact rat hepatocytes
208. Oxidation of the alcohol dehydrogenase inhibitor pyrazole to 4-hydroxypyrazole by microsomes. Effect of cytochrome P-450 inducing agents
209. Metabolism of pyrazole in rat
210. Metabolism of pyrazole. Structure elucidation of urinary metabolites
211. Comparative metabolism of zolazepam in rat, dog, and monkey
212. Tracazolate metabolites in rat tissue
213. Metabolism of tracazolate. Metabolites in dog and rat urine
214. Biotransformation in the monkey of cartazolate (SQ 65,396), a substituted pyrazolopyridine having anxiolytic activity
215. Metabolism of benzydamine hydrochloride
216. Metabolism of benzydamine hydrochloride. Species differences and the identification of unconjugated metabolites in rabbit urine
217. In vivo metabolism and antiinflammatory activity of benzydamine hydrochloride in rats treated with carrageenin
218. Metabolism of benzydamine
219. 14C-granisetron in rat, dog and man after intravenous and oral dosing
220. Functional, biochemical, and morphological hepatobiliary effects in rats chronically exposed to a steroidal antiandrogen
221. Metabolism of mepirizole. Isolation of a new metabolite from dog urine and species differences in urinary metabolites
222. Metabolic fate of 1-(4-methoxy-6-methyl-2-pyrimidinyl)-3-methyl-5-methoxypyrazole (mepirizole, DA-398) in rats and rabbits
223. Metabolism of the anticonvulsant agent zonisamide in the rat
224. Reductive metabolism of the anticonvulsant agent zonisamide, a 1,2-benzisoxazole derivative
225. Characterization of human liver microsomal cytochrome P450 involved in the reductive metabolism of zonisamide
226. Formation of reductive metabolite, 2-sulfamoylacetylphenol, from zonisamide in rat liver microsomes
227. Rat liver microsomal cytochrome P-450 responsible for reductive metabolism of zonisamide
228. Formation of 2-sulfamoylacetylphenol from zonisamide under aerobic conditions in rat liver microsomes
229. Involvement of mammalian liver cytosols and aldehyde oxidase in reductive metabolism of zonisamide
230. Absorption, metabolism, and excretion of risperidone in humans
231. The metabolism and excretion of risperidone after oral administration in rats and dogs
232. Application of hyphenated LC/NMR and LC/MS techniques in rapid identification of in vitro and in vivo metabolites of iloperidone
233. The absorption, distribution and metabolic fate of Danazol in rats, monkeys and human volunteers
234. Leflunomide: A review of its use in active rheumatoid arthritis
235. Metabolism and excretion of a new antipsychotic drug, ziprasidone, in humans
236. Characterization of the novel benzisothiazole ring-cleaved products of the antipsychotic drug ziprasidone
237. Metabolism and excretion of the novel antipsychotic drug ziprasidone in rats after oral administration of a mixture of 14C-and 3H-labeled ziprasidone
238. Characterization of in vitro metabolites of the antipsychotic drug tiospirone by mass spectrometry
239. Metabolism of the antipsychotic drug tiospirone in humans
240. Effects of the antifungal agents on oxidative drug metabolism: Clinical relevance
241. Formation of (R)-8-hydroxywarfarin in human liver microsomes. A new metabolic marker for the (S)-mephenytoin hydroxylase, P4502C19
242. Autocatalytic alkylation of the cytochrome P450 prosthetic haem group by 1-aminobenzotriazole
243. Selective inactivation of cytochrome P450 isozymes by suicide substrates
244. Inactivation of rabbit pulmonary cytochrome P450 in microsomes and isolated perfused lungs by the suicide substrate 1-aminobenzotriazole
245. Three N-aralkylated derivatives of 1-aminobenzotriazole as potent and isozyme-selective, mechanism-based inhibitors of guinea pig pulmonary cytohrome P450 in vitro
246. N-Araalkyl derivatives of 1-aminobenzotriazole as potent isozyme-selective mechanism based inhibitors of rabbit pulmonary cytochrome P450 in vivo
247. Autocatalytic inactivation of cytochrome P450 and chloroperoxidase by 1-aminobenzotriazole and other aryne precursors
248. N-Alkylaminobenzotriazoles as isozyme-selective suicide inhibitors of rabbit pulmonary microsomal cytochrome P450
249. Metabolism of the cytochrome P450 mechanism based inhibitor N-benzyl-1-aminobenzotriazole to products that covalently bind with protein in the guinea pig liver and lung microsomes: Comparative study with 1-aminobenzotriazole
250. 14C-estazolam in dogs and humans
251. Metabolism and fate of triazphos in rats
252. Novel quinuclidine-based ligands for the muscarinic cholinergic receptor
253. Novel 5-HT3 antagonists. Indole oxadiazoles
254. a, Log P and MedChem CLOGP fragment values of acidic heterocyclic potential bioisosteres
255. Picornavirus inhibitors: Trifluoromethyl substitution provides a global protective effect against hepatic metabolism
256. Selective inhibitors of monoamine oxidase. 3. Structure-activity relationship of tricyclics bearing imidazoline, oxadiazole, or tetrazole groups
257. The selective 5-HT1B receptor inverse agonist 1′-methyl-5-[[(2′-methyl-4′- (5-methyl-1,2,4-oxadiazol-3-yl)biphenyl-4-yl]carbonyl]- 2,3,6,7-tetrahydrospiro[furo[2,3-f]indole-3,4′-piperidine] (SB-224289) potently blocks terminal 5-HT autoreceptor function both in vitro and in vivo
258. 1,2,5-Oxadiazole N-oxide derivatives and related compounds as potential antitrypanosomal drugs: Structure-activity relationships
259. Metabolism by man of an anticonvulsant oxadiazole. Unusual metabolic route for tertiary amides
260. Metabolic studies with trans-5-amino-3-[2-(5-nitro-2-furyl)vinyl]-1,2,4-[514C]oxadiazole (SQ 18,506). 1. Reductive cleavage of the 1,2,4-oxadiazole ring
261. The use of liquid chromatography/thermospray mass spectrometry with online ultraviolet diode array and radiochemical detection: Characterization of the putative metabolites of U-78875 in female rat feces
262. Novel cleavage of the 1,2,4-oxadiazole ring in rat metabolism of SM-6586, a dihydropyridine calcium antagonist
263. Biological fate of sirdalud in animals and man
264. Identification and quantitative determination of a carboxylic and a mercapturic acid metabolite of etridiazole in urine of rat and man. Potential tools for biological monitoring
265. 1,2,3-Thiadiazoles: A novel heterocyclic heme ligand for the design of cytochrome P450 inhibitors
266. Tetrazoles
267. Clinically effective 6-ethyl-3-(1H-tetrazol-5-yl)chromone, (AA-344)
268. Synthesis and identification of a novel tetrazole metabolite of the angiotensin II receptor antagonist DuP 753
269. The metabolism of DuP 753, a nonpeptide angiotensin II receptor antagonist by rat, monkey, and human liver slices
270. Metabolism of losartan by polymorphic human UDP-glucuronosyltransferase (UGT)2B7
271. In vitro N-glucuronidation of SR-47436 (BMS 186295), a new AT1 nonpeptide angiotensin II receptor antagonist, by rat, monkey and human microsomal fractions
272. N-Glucuronidation reactions. I. Tetrazole N-glucuronidation of selected angiotensin II receptor antagonists in hepatic microsomes from rats, dogs, monkeys and humans
273. Characterization of 2-[[4-[[2-(1H-tetrazol-5-ylmethyl)phenyl]-methoxy]-phenoxy]methyl]quinoline N-glucuronidation by in vitro and in vivo approaches
274. Disposition of irbesartan, an angiotensin II AT1-receptor antagonist in mice, rats, rabbits, and macaques
275. Biotransformation of ibesartan in man
276. Disposition of DMP 811 (L-708,404), a potent angiotensin II receptor antagonist, in the rat, monkey, and chimpanzees
277. Absorption and glucuronidation of the angiotensin II receptor antagonist losartan by the rat intestine